112 related articles for article (PubMed ID: 11781652)
1. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia.
Tack DK; Letendre L; Kamath PS; Tefferi A
Bone Marrow Transplant; 2001 Nov; 28(9):895-7. PubMed ID: 11781652
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Alvarado Y; Tsimberidou A; Kantarjian H; Cortes J; Garcia-Manero G; Faderl S; Thomas D; Estey E; Giles FJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):87-90. PubMed ID: 12497211
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.
Cohen AD; Luger SM; Sickles C; Mangan PA; Porter DL; Schuster SJ; Tsai DE; Nasta S; Gewirtz AM; Stadtmauer EA
Bone Marrow Transplant; 2002 Jul; 30(1):23-8. PubMed ID: 12105773
[TBL] [Abstract][Full Text] [Related]
4. Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and..
Gordon LI
Bone Marrow Transplant; 2001 Nov; 28(9):811-2. PubMed ID: 11781639
[No Abstract] [Full Text] [Related]
5. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Giles FJ; Kantarjian HM; Kornblau SM; Thomas DA; Garcia-Manero G; Waddelow TA; David CL; Phan AT; Colburn DE; Rashid A; Estey EH
Cancer; 2001 Jul; 92(2):406-13. PubMed ID: 11466696
[TBL] [Abstract][Full Text] [Related]
6. Probable veno-occlusive disease after treatment with gemtuzumab ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosis.
O'Boyle KP; Murigeppa A; Jain D; Dauber L; Dutcher JP; Wiernik PH
Med Oncol; 2003; 20(4):379-84. PubMed ID: 14716035
[TBL] [Abstract][Full Text] [Related]
7. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Cortes J; Tsimberidou AM; Alvarez R; Thomas D; Beran M; Kantarjian H; Estey E; Giles FJ
Cancer Chemother Pharmacol; 2002 Dec; 50(6):497-500. PubMed ID: 12451477
[TBL] [Abstract][Full Text] [Related]
8. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
9. Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Ronconi S; Visani G; Baccarani M
Haematologica; 2003 Dec; 88(12):ECR37. PubMed ID: 14688010
[No Abstract] [Full Text] [Related]
10. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Tsimberidou AM; Estey E; Cortes JE; Garcia-Manero G; Faderl S; Verstovsek S; Thomas DA; Ferrajoli A; Keating MJ; O'Brien S; Kantarjian HM; Giles FJ
Cancer Chemother Pharmacol; 2003 Dec; 52(6):449-52. PubMed ID: 13680159
[TBL] [Abstract][Full Text] [Related]
11. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
[TBL] [Abstract][Full Text] [Related]
12. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.
Giles FJ; Cortes JE; Halliburton TA; Mallard SJ; Estey EH; Waddelow TA; Lim JT
Ann Pharmacother; 2003 Sep; 37(9):1182-5. PubMed ID: 12921496
[TBL] [Abstract][Full Text] [Related]
13. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
Leopold LH; Berger MS; Feingold J
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S29-34. PubMed ID: 11970768
[TBL] [Abstract][Full Text] [Related]
14. Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
Giles F; Garcia-Manero G; O'Brien S; Estey E; Kantarjian H
Acta Haematol; 2002; 108(3):164-7. PubMed ID: 12373091
[No Abstract] [Full Text] [Related]
15. Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience.
Specchia G; Pastore D; Carluccio P; Spinosa G; Giannoccaro M; Rizzi R; Mestice A; Liso V
Ann Hematol; 2007 Jun; 86(6):425-8. PubMed ID: 17364181
[TBL] [Abstract][Full Text] [Related]
16. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Asano H; Yamamoto G; Hosoi M; Takahashi T; Hangaishi A; Kurokawa M
Leuk Res; 2010 Jul; 34(7):e152-3. PubMed ID: 20061019
[No Abstract] [Full Text] [Related]
17. [Standard therapies for acute myeloid leukemia].
Matsumura I
Rinsho Ketsueki; 2009 Oct; 50(10):1389-400. PubMed ID: 19915347
[No Abstract] [Full Text] [Related]
18. A Case of Pulmonary Veno-occlusive Disease Following Hepatic Veno-occlusive Disease After Autologous Hematopoietic Stem Cell Transplantation for Neuroblastoma.
Isshiki K; Shima H; Yamazaki F; Takenouchi T; Shimada H
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e677-e679. PubMed ID: 31335821
[TBL] [Abstract][Full Text] [Related]
19. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Tsimberidou A; Estey E; Cortes J; Thomas D; Faderl S; Verstovsek S; Garcia-Manero G; Keating M; Albitar M; O'Brien S; Kantarjian H; Giles F
Cancer; 2003 Mar; 97(6):1481-7. PubMed ID: 12627513
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of gemtuzumab-associated hepatic sinusoidal occlusion syndrome after hematopoietic stem cell transplant.
Aplenc R; Vachani A; Han P; Glatfelter W; Sievers EL
Acta Haematol; 2003; 110(4):207-10. PubMed ID: 14663169
[No Abstract] [Full Text] [Related]
[Next] [New Search]
